DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20180592

Frequency of thyroid dysfunctions among Nigerian patients with vitiligo

Ehimen P. Odum, Collins Amadi

Abstract


Background: Vitiligo is associated with varying degrees of thyroid dysfunctions. This study was aimed to evaluate the thyroid dysfunctions in patients with vitiligo in Port Harcourt, Nigeria, West Africa.

Methods: A retrospective, descriptive, cross-sectional analysis of thyroid function tests variables of 105 vitiligo patients who visited the Department of Chemical Pathology and Metabolic Medicine of the University of Port Harcourt Teaching Hospital between 1st January 2012 and 31st December 2016 was conducted. Records of age, sex, thyroid stimulating hormone, total thyroxine, total triiodothyronine was collected and analyzed using Shapiro-Wilk, descriptive, chi-square, Fisher’s exact, and Pearson’s tests. A statistical significance of p <0.05 was applied.

Results: Females predominated among study cohort (61.9% female versus 38.1% male; p = 0.015). Most patients were less than 30 years old in both sexes. 26.7% (37 out of 105) had various degrees of thyroid dysfunctions. Among this 26.7% (37) with various thyroid dysfunctions, are 28 (75%) females and 9 (25%) males. These dysfunctions include primary hypothyroidism (6.7%), primary hyperthyroidism (1%), subclinical hypothyroidism (17.1%) and subclinical hyperthyroidism (1.9%), while the majority were euthyroid (73.3%). Subclinical hypothyroidism was the most common disorder (n = 18; 17.2%) with female preponderance (females n = 11; 61% versus males n = 7; 39%).

Conclusions: This study confirms high frequency of thyroid dysfunctions among vitiligo patients. The culture of regular assessment of thyroid function should be mandatory among patients with vitiligo.


Keywords


Age, Nigeria, Sex, Subclinical hypothyroidism, Vitiligo

Full Text:

PDF

References


Gauthier Y, Cario Andre M, Taieb A. A critical appraisal of vitiligo etiologic theories: is Melanocyte loss a melanocytorrhagy?. Pigment Cell Res. 2003;16(4):322-32.

Alkhateeb A, Fain PR, Thody A, Bennet DC, Spritz RA. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res. 2003;16(3):208-14.

Onayemi O, Isezuo SA, Njoku CH. Prevalence of different skin conditions in an outpatient setting in north-west Nigeria. Int J Dermatol. 2005;44(1):7-11.

Altraide DD, George IO, Otike-Odibe B. Vitiligo: A hospital based study in southern Nigeria. Port Harcourt M J. 2009;4(2)

Kovacs SO. Vitiligo. J Am Acad Dermatol. 1998;38(5):647-66.

Malhota N, Dytoc M. The Pathogenesis of Vitiligo. J Cutan Med Surg. 2013;17(3):153-72.

Njoo MD, Westerhof W. Vitiligo Pathogenesis and treatment. Am J Clin Dermatol. 2001;2(3):167-81.

Ongenae K, Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 2003;16(2):90-100.

Hegedus L, Heidenheim M, Gervil M, Hjalgrim H, Hoeier-Madsen M. High frequency of thyroid dysfunction in patients with Vitiligo. Acta Dem Venereol. 1994;74(2):120-3.

Narita T, Oisio N, Fukai K, Kabashima K, Kawa A, Suzuki T. Generalized vitiligo and associated autoimmune diseases in Japanese patients and their families. Allergol Int. 2011;60:505-8.

Numes DH, Esser LMH. Vitiligo epidemiologic profile and the association with thyroid disease. An Bras Dermatol. 2011;86(2);241-8.

Kumar KV, Priya S, Sharma R, Kapoor U, Saini M, Bisht YS. Autoimmune thyroid disease in patients with vitiligo: prevalence study study in India. Endocr Pract. 2012;18(2):194-9.

Dave S, D’Souza M, Thapp DM. High frequency of thyroid dysfunction in Indian patients with vitiligo. Indian J Dermatol. 2003;48(2):68-72.

Wellinton GW, Levell NJ. “Vitiligo: the historical course of depigmentation.” In J Dermatol. 2007;46(9);990-5.

Arican O, Koc K, Ersol L. Clinical characteristics in 113 Turkish vitiligo patients. Acta Dermatovenereol Alp Panonic Adria. 2008;17(3):129-32.

Onunu AN, Kubeyinje EP. Vitiligo in the Nigerian African: a study of 351 patients in Benin City, Nigeria. Int J Dermatol. 2003;4(10):800-2.

Mohamed GF, Gonaa AHA, Al-Dhubaibi MS. Highlights in pathogenesis of vitiligo. World J Clin Cases. 2015;(3):221-30.

Rezaei N, Gawalas NG, Weetman AP, Kemp EH. Autoimmunity as an etiological factor in vitiligo. J Eur Acad Dermatol Venereal. 2007;21(7):865-76.

Robert P. Ueber die Vitiligo. Dermatologica. 1941;84:317-9.

Handa S, Kaur I. Vitiligo: clinical findings in 1436 patients. J Dermatol. 1999;26;653-7.

Majumber PP, Nordlund JJ, Nath SK. Pattern of familial aggregation of vitiligo. Arch Dermatol. 1993;129(8):994-8.

Jishna P, Binitha MP, Abdul Latheef EN, Anikumari VP. Prevalence of thyroid dysfunctions and anti-thyroid peroxidase antibodies in vitiligo patients. Int J Res Dermatol. 2017;3(1):140-4.

Asfar FS, Isleton F. Prevalence of thyroid function test abnormalities and thyroid antibodies in children with vitiligo. Indian J Endocrinol Metab. 2013;17(6):1096-99.

Gopal KV, Rao GR, Kumar YH. Increases prevalence of thyroid dysfunction and diabetes mellitus in Indian vitiligo patients: A case-control study. Indian Dermatol Online. 2014;5(4):456-60.

Huggins RH, Janus CA, Schwartz RA. Vitiligo: a sign of systemic disease. Indian J Dermatol Venereol Leprol. 2006;72(1):68-71.

Lacovelli P, Sinagra JL, Vidolin AP, Marenda S, Capitanio B, Leone G, et al. Relevance of Thyroiditis and other autoimmune diseases in children with vitiligo. Dermatol. 2005;210(1):26-30.

Zadik Z. Overuse and misuse of thyroid function test in pediatrics. J Pediatr Endocrinol Metab. 2009;22(10):875-6.